Semaxanib (SU5416) Mechanism of Action: VEGFR2 Inhibition in Pulmonary Endothelial Cell Research

Semaxanib (SU5416) MOA:Targeting VEGFR2/VEGF Signaling Pathway for Pulmonary Arterial Hypertension Research

🎯 check Semaxanib (SU5416) product page

Semaxanib (SU5416) is a potent, selective, ATP-competitive VEGFR-2 tyrosine kinase inhibitor. It affects VEGF/VEGFR signaling by binding to the ATP-binding site of the receptor kinase domain to block autophosphorylation, effectively inhibiting tumor angiogenesis and endothelial cell proliferation.

Primary Applications and Mechanism of Action